Savara Inc Impairment of Intangible Assets, Finite-lived
Savara Inc (SVRA) reported Impairment of Intangible Assets, Finite-lived of $21.69 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2020-03-12
- Savara Inc impairment of intangible assets, finite-lived for the quarter ending 2018-12-31 was $0.00.
- Savara Inc impairment of intangible assets, finite-lived for the quarter ending 2018-09-30 was $0.00.
- Savara Inc impairment of intangible assets, finite-lived for the quarter ending 2018-06-30 was $0.00.
- Savara Inc impairment of intangible assets, finite-lived for the quarter ending 2018-03-31 was $21.69M.
- Savara Inc impairment of intangible assets, finite-lived for fiscal 2018 was $21.69M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $21.69M 10-K · filed 2020-03-12 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $21.69M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $21.69M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $21.69M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |